This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

AcutePreventiveSafetyDosingDosingDosingMOASavings & SupportSavings
& SupportSavings & SupportFormulary CoverageResourcesResourcesProvider & Patient EducationPrior Authorization
Prescribing InformationIndicationsPatient InformationPatient Site
For the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adultsSavings & SupportLoading

Order Samples

Loading Rapid relief.
Powerful prevention. Nurtec ODT does both.1-3
For acute treatment at 2 hours, 21.2% of patients on Nurtec ODT (n=142/669) achieved migraine pain freedom vs 10.9% on placebo (n=74/682) (Δ10.3%*; P<0.001), and 35.1% achieved freedom from most bothersome symptom (MBS) vs 26.8% on placebo (Δ8.3%*; P=0.001) (coprimary endpoints). For preventive treatment, rimegepant 75 mg (n=348) reduced patients' monthly migraine days (MMDs) by 4.3 days vs 3.5 days for those on placebo (n=347) at weeks 9–12 compared with baseline observation period (Δ-0.8†; P=0.01).1-3
For the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults Savings & Support Loading Order Samples Loading Rapid relief.
Powerful prevention. Nurtec ODT does both.1-3 For acute treatment at 2 hours, 21.2% of patients on Nurtec ODT (n=142/669) achieved migraine pain freedom vs 10.9% on placebo (n=74/682) (Δ10.3%*; P<0.001), and 35.1% achieved freedom from most bothersome symptom (MBS) vs 26.8% on placebo (Δ8.3%*; P=0.001) (coprimary endpoints). For preventive treatment, rimegepant 75 mg (n=348) reduced patients' monthly migraine days (MMDs) by 4.3 days vs 3.5 days for those on placebo (n=347) at weeks 9–12 compared with baseline observation period (Δ-0.8†; P=0.01).1-3 Patient access
Most insured adults in the US can get Nurtec ODT through their insurance.‡
Learn about coverage
Loading Learn about coverage Loading Dosing
Flexible dosing to meet your patients’ needs.1
View dosing information
Loading View dosing information Loading Safety data

Safety profile studied up to 52 weeks for both acute and preventive migraine treatment.1

View safety profile
Loading View safety profile LoadingDifference from placebo based on Cochran-Mantel-Haenszel method.3Analyzed using a generalized linear mixed-effects model with treatment group, preventive migraine medication use at randomization, study month, and month-by-treatment group interaction as fixed effects and participant as random effect.2Per Managed Markets Insight & Technology, LLC since 01/27/25. Formulary data are current as of May 2025. The information provided is not a guarantee of coverage or payment (partial or full), and is subject to change without notice. Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Please confirm coverage with each patient’s plan. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein.
Nurtec ODT is the only
gepant compared with an
injectable CGRP mAb in a
head-to-head study4
Nurtec ODT is the only gepant compared with an
injectable CGRP mAb in a head-to-head study4
View the studyLoadingView the studyLoading Treatment in one orally disintegrating tablet1
Taken as needed to treat migraine attacks. Help patients take action against migraine attacks with a single dose. 
  • The recommended dose of Nurtec ODT for acute treatment is 75 mg taken orally, as needed
 Treatment in one orally disintegrating tablet1 View acute efficacy data Loading
The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established.
 Prevention without an injection or daily pill1 Prevention without an injection or daily pill1
Every-other-day dosing to help prevent migraine. Help patients reduce their MMDs with one medication. 
  • The recommended dose of Nurtec ODT for preventive treatment is 75 mg taken orally, every other day
 View preventive efficacy data Loading97% commercial
insurance coverage§

Learn more about how to access savings and support.

 Savings & Support LoadingTarget a key mediator in migraine5-9

CGRP levels are elevated during a migraine attack. Learn more about the multifactorial pathophysiology of migraine and how Nurtec ODT is designed to work.

 View mechanism of action Loading
Target a key mediator in migraine5‑9

CGRP levels are elevated during a migraine attack. Learn more about the multifactorial pathophysiology of migraine and how Nurtec ODT is designed to work.

 View mechanism of action LoadingCGRP=calcitonin gene-related peptide; mAb=monoclonal antibody.Per Managed Markets Insight & Technology, LLC since 01/27/25. Formulary data are current as of May 2025. The information provided is not a guarantee of coverage or payment (partial or full), and is subject to change without notice. Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Please confirm coverage with each patient’s plan. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein.References:Nurtec ODT. Package insert. Pfizer Inc.Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60.Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745.Schwedt TJ, Myers Oakes TM, Martinez JM, et al. Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized, controlled clinical trial. Neurol Ther. 2024;13(1):85-105.Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573-582.Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338-350.Tepper SJ. CGRP and headache: a brief review. Neurol Sci. 2019;40(suppl 1):99-105.Fabbretti E, D’Arco M, Fabbro A, Simonetti M, Nistri A, Giniatullin R. Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J Neurosci. 2006;26(23):6163-6171.Guan LC, Dong X, Green DP. Roles of mast cells and their interactions with the trigeminal nerve in migraine headache. Mol Pain. 2023;19:1-10. Have samples of Nurtec ODT delivered to your office Get samples Loading Get samples Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-NNT-USA-4379
INDICATIONSNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine

Please click here for full Prescribing Information.
Important Safety Information Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included anaphylaxis, dyspnea, and rash and can occur days after administration. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Nurtec ODT, in the postmarketing setting.Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted. Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Nurtec ODT.If signs or symptoms of Raynaud’s phenomenon develop, discontinue Nurtec ODT. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for and informed about the possibility of worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions for Nurtec ODT vs placebo were nausea (2.7% vs 0.8%) and abdominal pain/dyspepsia (2.4% vs 0.8%). Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4 or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp. Use in Specific Populations: Pregnancy: It is not known if Nurtec ODT can harm an unborn baby.
Lactation: The transfer of rimegepant into breast milk is low (<1%). Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.IndicationsNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine

Please click here for full Prescribing Information.